Global ETD Search

161	Intra-nucleus accumbens shell injections of R(+)- and S(-)- baclofen bidirectionally alter binge-like ethanol, but not saccharin, intake in C57Bl/6J mice Kasten, Chelsea Rae January 2014 (has links) Indiana University-Purdue University Indianapolis (IUPUI) / It has been proposed that the GABAB receptor subtype plays a role in alcoholism and alcohol use disorders (AUDs) (Cousins et al., 2002; Agabio et al., 2012). Specifically, the GABAB agonist baclofen has been looked at extensively in clinical and pre-clinical studies. In various animal models of chronic and intermittent consumption, baclofen has been shown to both increase (Petry, 1997; Smith et al., 1999; Czachowski et al., 2006; Moore et al., 2007) and decrease (Colombo et al., 2000; 2002; 2005; Stromberg, 2004; Moore et al., 2009) drinking. A critical issue in determining pharmacological effects of a drug is using the appropriate animal model. The drinking-in-the-dark (DID) model, developed by Rhodes et al. (2005, 2007), produces high levels of drinking in a binge-like paradigm and has been used to assess many pharmacological targets (e.g. Kamdar et al., 2007; Gupta et al., 2008; Moore et al., 2007; 2009). While DID produces high-levels of binge drinking, it is unclear what areas of the brain are involved in this behavior. A direct way to target areas that are believed to be involved in the circuitry of particular behaviors is through microinjection of drugs (Kiianmaa et al., 2003). Of particular recent interest involving motivated behaviors and addiction is the nucleus accumbens (Acb) (Everitt & Robbins, 2005); specifically the accumbens shell (AcbSh) (e.g. Rewal et al., 2009, 2012; Nie et al., 2011; Leriche et al., 2008). The current study aimed to investigate the role of GABAB receptors in the AcbSh by examining the ability of two different enantiomers of baclofen to alter ethanol and saccharin intake in male C57BL/6J (B6) mice. B6 mice underwent bilateral cannulation surgery targeting the AcbSh. After 48 hours of recovery time, animals began a five day Drinking-in-the-Dark (DID) procedure where they received 20% ethanol or 0.2% saccharin for two hours, three hours into the dark cycle, each day. Throughout the five drinking sessions, animals were kept in home-cage locomotor activity chambers to monitor activity throughout the drinking cycle. Day 4 drinking was immediately preceded by a mock microinjection, whereas Day 5 drinking was immediately preceded by a drug microinjection. Microinjection of one of five doses of baclofen was given in ng/side dissolved in 200 µl of aCSF (aCSF alone, 0.02 R(+)-, 0.04 R(+)-, 0.08 S(-)-, or 0,16 S(-)-). Intake was recorded every twenty minutes on Days 4 and 5. Retro-orbital sinus blood samples were taken from ethanol animals immediately following the Day 5 drinking period to determine blood ethanol concentrations (BECs). A one-way ANOVA on total Day 4 ethanol consumption revealed no baseline differences between dose groups. A one-way ANOVA on total Day 5 ethanol consumption revealed that the 0.04 R(+)- baclofen dose reduced total drinking, but the 0.16 S(-)- baclofen dose increased total drinking (p’s<0.05). This pattern was reflected in the BECs; 0.04 R(+)- baclofen reduced BECs, whereas 0.16 S(-)- baclofen increased BECs (p’s<0.05). These results were also time-dependent, with R(+)-baclofen reducing drinking in the first 20 minutes of the session and S(-)- increasing drinking in the last 40 minutes of the session. There were no effects on saccharin intake. An issue with the locomotor activity boxes led to unreliable locomotor activity counts. However, because there were no drug effects on saccharin consumption, it was concluded that locomotor effects did not contribute to the decreases or increases in ethanol consumption. These results further implicate the role of GABAB receptors in modulating ethanol intake. The bidirectional effects shown highlight the importance of considering enantioselective drug effects when interpreting data. Finally, these results also support previous conclusions that the AcbSh plays an important role in modulating use of drugs of abuse, but not other reinforcers. Alcoholism -- Animal models Neural receptors -- Analysis GABA -- Agonists -- Physiological effect Aminobutyric acid -- Research Nucleus accumbens -- Research Saccharin -- Animal models
162	大腦度巴胺系統在大鼠操作式制約行為中所扮演的角色：以時間為主 / The Role of Brain Dopamine Systems on Operant Conditioned Behavior in the Rat: From Temporal Perspective 鄭瑞光 Unknown Date (has links) 周邊注射安非它命能夠影響動物受試在表現與時間知覺有關的操作式制約行為作業，歷來被研究者認為是大腦多巴胺神經系統與動物時間知覺系統有關的主要證據之一。本研究所共同採用的研究方法為先注射多巴胺受體專屬拮抗劑再於大鼠受試周邊腹腔注射安非它命的方式探討安非它命影響大鼠時間知覺的大腦機制為何。實驗一利用區辨性增強低頻反應作業觀察周邊注射多巴胺受體專屬拮抗劑何者可以反制周邊安非它命對此作業的影響效果，結果發現多巴胺D1受體拮抗劑SCH23390與D2受體拮抗劑raclopride均可反制周邊安非它命的效果。實驗二同樣利用區辨性增強低頻反應作業，但是將SCH23390與raclopride分別注入海馬迴、背側中區紋狀體、腹側側邊紋狀體、依核、內側前額葉皮質以及腹側頂蓋區等六個部位，觀察何種多巴胺受體拮抗劑可在那些大腦部位產生反制周邊安非它命的效果。結果發現SCH23390可在海馬迴、依核、內側前額葉皮質以及腹側頂蓋區等四個部位產生反制周邊安非它命的效果，而raclopride可在腹側側邊紋狀體與內側前額葉皮質兩個部位產生同樣的反制效果。實驗三利用高峰時距作業觀察SCH23390在海馬迴與內側前額葉皮質是否能反制周邊安非它命對此作業的影響效果，結果發現SCH23390僅在海馬迴會影響大鼠受試的正常表現，特別是在與周邊安非它命同時注射的時候。綜合以上結果顯示，周邊注射安非它命能夠使大鼠受試在區辨性增強低頻反應作業當中表現出時間知覺變快的傾向，這個效果需要同時透過大腦內的海馬迴、依核、內側前額葉皮質以及腹側頂蓋區的多巴胺D1類受體和腹側側邊紋狀體與內側前額葉皮質的多巴胺D2類受體。 / The central dopaminergic system has been hypothesized to play a role in time perception based on the results that peripheral injections of d-amphetamine alter the responses in time-related operant conditioned behavioral tasks. The present study investigated the effect by injecting specific dopamine receptor antagonists before peripheral d-amphetamine injections in rats. Data from Experiment I showed that both peripheral the dopamine receptor D1 antagonist SCH23390 and D2 antagonist raclopride could attenuate the response alteration on differential reinforcement of low-rates responding task induced by peripheral d-amphetamine. By using the DRL task, Experiment 2 employed the microjeciton technique to determine the neural substrates for the DA receptor antagonist to attenuate the effect of peripheral d-amphetamine. The infusion sites for DA receptor antagonist were the hippocampus, the dorsomedial striatum, the ventrolateral striatum, the nucleus accumbens, the medial prefrontal cortex, and the ventral tegme ntal area. The results showed that SCH23390 infused into the hippocampus, the nucleus accumbens, the medial prefrontal cortex, the ventral tegmental area could attenuate the effect induced by peripheral d-amphetamine, and such attenuation effects were also observed for raclopride infused into the ventrolateral striatum, the medial prefrontal cortex. Experiment 3 tried to confirm the results of Experiment 2 by microinjecting SCH23390 in hippocampus and medial prefrontal cortex under peak-interval task. Only SCH23390 in the hippocampus altered the subject's normal performance in this task especially when combined with peripheral injection of d-amphetamine. In conclusion, that the response alteration on the DRL task induced by peripheral injection ofd-amphetamine suggests the subject's timing perception being accelerated. These effects of d-amphetamine were mediated by simultaneous activation of multiple dopamine receptor subtypes including D1 receptors located in the hippocampus, nucleus accumbens, medial pref rontal cortex, ventral tegmental area, as well as D2 receptors located in the ventrolateral striatum, medial prefrontal cortex. 時間知覺多巴胺系統區辨性增低頻反應作業高峰時距作業海馬迴紋狀體依核內側前額葉皮質腹側頂蓋區 time perception dopamine system peak-interval task hippocampus striatum nucleus accumbens medial prefrontal cortex ventral tegmental area
163	Study of the interaction between 3,4 methylenedioximethamphetamine and the endocannabinoid system Touriño Raposo, Clara 17 February 2009 (has links) La 3,4-metilendioximetamfetamina (MDMA, èxtasi) i el cannabis són dues drogues les quals es consumeixen conjuntament de manera habitual. Malgrat que tots dos compostos presenten propietats reforçant i potencial addictiu, també tenen propietats farmacològiques oposades. La MDMA es una droga psicoestimulant, la qual causa hiperlocomoció, hipertèrmia, resposted de tipus asiogènic i neurotoxicitat. Per altra banda el Δ9-tetrahydrocannabinol (THC), principal compost psicoactiu del cannabis, posseeix efectes relaxants, hipolocomotors, hipotèrmics i neuroprotectors. Els efectes de la MDMA i el THC al sistema nerviós central es troben mediats per dos mecanismes notablement diferents. La MDMA augmenta els nivells extracel·lulars de dopamina i serotonina, mentre que el THC produeix l'activació del receptor cannabinoide CB1. Cal destacar a més que les interaccions entre els sistemes monoaminèrgic i endocannabinoide s'observa de manera freqüent en l'organisme.En el present estudi hem explorat la implicació del sistema endocannabinoide i la MDMA en diversos aspectes. Per una banda el receptor cannabinoide CB1 juga un important paper en els efectes hiperlocomotors i hipertèrmics, i en les respostes de tipus ansiogènic produïdes per la MDMA. Curiosament, encara que el receptor CB1 no participa en els efectes recompensants primaris de la MDMA, és imprescindible per que tinguin lloc els seus efectes reforçants. Així mateix, l'alliberació de serotonina per part de la MDMA redueix de manera dosi-depenent la simptomatologia física causada pel síndrome d'abstinència a cannabinoides precipitada per un antagonista del receptor CB1. Finalment, el tractament amb THC era capaç de prevenir la hipertèrmia, activació glial, estrès oxidatiu i pèrdua de terminals causada per la MDMA. Com a conseqüència el THC exerceix un efecte neuroprotector contra la neurotoxicitat induïda per la MDMA. / 3,4-methylenedioximethamphetamine (MDMA, ecstasy) and cannabis are two drugs frequently consumed in combination. Despite both compounds have rewarding properties and abuse liability, they show opposite pharmacological properties. On the one hand, MDMA is a psychostimulant drug with hyperlocomotor, hyperthermic, anxiogenic-like and neurotoxic effects. On the other hand, Δ9-tetrahydrocannabinol (THC), the main psychoactive compound of cannabis, has relaxant, hypolocomotor, hypothermic and neuroprotective properties. The effects of MDMA and THC in the central nervous system are mediated by two different mechanisms. MDMA enhances the extracellular levels of dopamine and serotonin, whereas THC activates the CB1 cannabinoid receptor. Likewise, interactions between the monoaminergic and the endogenous cannabinoid system have been frequently observed.In the current study, we explored the involvement of CB1 cannabinoid receptor on the hyperlocomotor, hyperthermic, anxiogenic-like, rewarding and reinforcing effects of MDMA. We also studied the effect of acute and chronic administration of MDMA on rimonabant-precipitated THC withdrawal syndrome. Furthermore, we explored the neuroprotective effects of THC on MDMA-induced neurotoxicity.As a result of this study we may conclude that endocannabinoid system and MDMA interact in a wide variety of aspects. CB1 receptor plays an important role on the hyperlocomotor, hyperthermic, and anxiogenic-like effects of MDMA. Interestingly, CB1 receptor is essential for the reinforcing but not the primary rewarding properties of MDMA. In addition, the release of serotonin by MDMA dose-dependently reduced the severity of THC withdrawal syndrome triggered by a CB1 antagonist. Finally, pretreatment with THC prevented the hyperthermia, glial activation, oxidative stress and terminal loss caused by MDMA. Consequently, THC exerts a neuroprotective effect against MDMA-induced neurotoxicity. tremolor transportador de dopamina tirosina hidroxilasa THC temperatura corporal sintasa d'òxid nítric síndrome d'abstinència serotonina rotarod rimonabant reforç recompensa receptor cannabinoide Ptosis proteïna glial fibrilar acídica preferència de plaça condicionada piloerecció pèrdua de terminals nucli accumbens neuroprotecció neurotoxicitat microglia microdialisis MDMA masticació laberint en creu elevat infusió inflamació immunohistoquímica hipotèrmia hipolocomoció hipertèrmia hiperlocomoció glutamat èxtasi estriat dopamina diarrea dependència DAT dany neuronal coordinació motora CD11b CB2 CB1 autoadministració atàxia astròcits anxiolític anxiogènic ansietat activitat locomotora abstinència 4-metilendioximetamfetamina 3 Δ9-tetrahydrocannabinol western blot Δ9-tetrahydrocannabinol 3 4-methylenedioximethamphetamine abstinence anxiety anxiogenic anxiolytic astrocytes ataxia body temperature 615 616.8

Page generated in 0.055 seconds